Original Article
Hematopoietic Stem-Cell Transplantation in Globoid-Cell Leukodystrophy
N Engl J Med 1998; 338:1119-1127April 16, 1998
- Abstract
Background
Globoid-cell leukodystrophy is caused by a deficiency of galactocerebrosidase, which results in progressive central nervous system deterioration. We investigated whether allogeneic hematopoietic stem-cell transplantation can provide a source of leukocyte galactocerebrosidase and thereby prevent the decline of central nervous system function in patients with the disease.
Methods
Five children with globoid-cell leukodystrophy (one with the infantile type and four with late-onset disease) were treated with allogeneic hematopoietic stem-cell transplantation. Measurement of leukocyte galactocerebrosidase levels, neurologic examinations, neuropsychological tests, magnetic resonance imaging of the central nervous system, cerebrospinal fluid protein assays, and neurophysiologic measurements were performed before and after transplantation, with follow-up ranging from one to nine years.
Results
Engraftment of donor-derived hematopoietic cells occurred in all patients and was followed by restoration of normal leukocyte galactocerebrosidase levels. In the four patients with late-onset disease, the central nervous system deterioration was reversed, and in the patient with the infantile form of the disease, signs and symptoms have not appeared. Magnetic resonance imaging showed a decrease in signal intensity in the three patients with late-onset disease who were assessed both before and after transplantation. Abnormalities in cerebrospinal fluid total protein levels were corrected in three patients with late-onset disease and substantially reduced in the patient with the infantile form.
Conclusions
Central nervous system manifestations of globoid-cell leukodystrophy can be reversed by allogeneic hematopoietic stem-cell transplantation.
Media in This Article
Figure 3
Cerebrospinal Fluid Total Protein Levels in Four Patients with Globoid-Cell Leukodystrophy before and after Hematopoietic Stem-Cell Transplantation.Figure 5
Median Nerve Conduction Velocity Measured before and after Hematopoietic Stem-Cell Transplantation in Patient 4.Article Activity
- Article
Globoid-cell leukodystrophy is an autosomal recessive disease due to greatly diminished or absent activity of the lysosomal enzyme galactocerebrosidase.1 The disease is characterized by the progressive loss of central and peripheral myelin and by spasticity, dementia, and peripheral neuropathy. It ends in a chronic vegetative state and early death. The more common form begins in early infancy and is rapidly progressive, often leading to death within two years. The late-onset form typically begins later in childhood, has a more insidious onset, and progresses over a period of several years to death.2,3
Hematopoietic stem-cell transplantation has been shown to alter the course of some but not all lysosomal and peroxisomal disorders.4 Donor leukocytes provide the deficient enzyme, which enters the central nervous system.5,6 We used transplantation with allogeneic hematopoietic stem cells to treat five patients with globoid-cell leukodystrophy. In four of these patients, clinical central nervous system abnormalities were present before transplantation. The anticipated development or progression of signs and symptoms was arrested after engraftment, thus supporting the hypothesis that allogeneic hematopoietic stem-cell transplantation can be effective in patients with globoid-cell leukodystrophy.
Methods
The patients were referred for treatment to the University of Minnesota at Minneapolis, the Université Catholique de Louvain in Brussels, Belgium, or Duke University School of Medicine in Durham, North Carolina, where approval by the institutional review boards and parental consent for participation in the study were obtained. Table 1Table 1
Characteristics of the Five Patients with Globoid-Cell Leukodystrophy. shows the characteristics of the five patients. Four of the patients received marrow from an HLA-identical sibling; one was treated with unrelated umbilical-cord blood (with one HLA-DR mismatch). The preparative regimens for each patient are listed in Table 1. All patients received cyclosporine with or without methylprednisolone for prophylaxis against graft-versus-host disease. Engraftment status was studied immediately after transplantation and annually thereafter by quantitation of leukocyte galactocerebrosidase activity. We confirmed engraftment by DNA analysis or determination of the sex chromosomes of leukocytes in the recipient's blood.Leukocyte galactocerebrosidase levels were analyzed by established techniques based on the hydrolysis of radioactively labeled galactocerebroside.2,3,7 The values were recorded in nanomoles per hour per milligram of protein in peripheral leukocytes. The mean (±SD) normal range for leukocyte galactocerebrosidase activity is 2.6±1.8 nmol per hour per milligram of protein.
Neuropsychological examinations were performed in three of the patients with late-onset disease. The tests, which were part of an established battery used for patients with storage diseases, included measures of intelligence, language, perception, attention, memory, and motor function.4 Each of the tests measures specific areas of brain function and has established normal values. A composite listing of the test manuals we used is available elsewhere (NAPS).
Neurologic examinations were performed at each visit. Neurophysiologic studies included standardized electroencephalography, measurement of visual evoked responses, and studies of nerve conduction velocity.8 Magnetic resonance imaging (MRI) scans were reviewed and severity scores were calculated to provide a numerical statement of areas of brain involved (higher scores indicate more severe disease, with 0 denoting normal and 30 denoting the most severe disease).9 Cerebrospinal fluid total protein, the albumin index (a measure of the integrity of the blood–brain barrier), and the IgG index (a measure of central nervous system synthesis of IgG) were measured by standard techniques.10-13
Results
All five children tolerated transplantation with relative ease. The absolute neutrophil count rose to 500 per cubic millimeter or higher by day 11, day 19, day 15, day 20, and day 12 after transplantation in Patients 1 through 5, respectively. DNA analysis or sex-chromosome analysis of peripheral-blood leukocytes or both were performed immediately after the transplantation and throughout follow-up. Of the cells examined, all were of donor origin for the first four patients and 85 percent were the donor's in the case of the fifth patient. Graft-versus-host disease did not occur in Patients 2 and 5. Grade II acute graft-versus-host disease of the skin was noted in Patient 1. Minimal skin involvement of chronic graft-versus-host disease, lasting for three months, occurred in Patient 3 after grade I acute graft-versus-host disease. Patient 4 had grade I graft-versus-host disease (with skin involvement only).
Figure 1Figure 1
Leukocyte Galactocerebrosidase Activity in Five Patients with Globoid-Cell Leukodystrophy before and after Hematopoietic Stem-Cell Transplantation. shows leukocyte galactocerebrosidase levels at the time of diagnosis and after transplantation. The recipients' leukocyte enzyme activity, although greater than the levels in the donors during the first year after transplantation, became equivalent to those of the donors in subsequent years. Donor enzyme levels were measured before transplantation.Patient 1
At the age of five years, Patient 1 had decreased visual acuity, and optic atrophy was diagnosed. Her school performance gradually deteriorated after eight years of age. The diagnosis of globoid-cell leukodystrophy was established by enzymatic assay when she was eight years old. Hand tremors and ataxia began at nine years of age, and a positive Romberg's test, diminished vibratory and positional sensation in the legs and feet, and hypothenar muscle atrophy were noted on neurologic examination. At the age of 11 years she received a marrow transplant from an HLA-identical sibling who had normal enzymatic activity (2.4 nmol per hour per milligram of protein) but who was demonstrated by genomic testing to be a carrier of globoid-cell leukodystrophy.
The patient's tremors and ataxia disappeared by six months after engraftment.14 One year later, motor incoordination and stumbling were no longer evident. Nine years after transplantation, her neurologic condition remains stable. She works as a credit-control clerk and telephone receptionist. She is independent in the activities of daily living.
Before transplantation, Patient 1 had been failing in school and was unable to identify common objects in pictures (visual agnosia). Subsequently, her schoolwork improved, and she graduated from high school. She continues to have difficulties in visual–spatial perception. The neuropsychological data indicate improving skills and no signs of deterioration (Table 2Table 2
Standard Scores of Patients 1, 3, and 4 at Base Line and at the Most Recent Visit, for Each Neuropsychological Domain.).Before transplantation, visual evoked responses (an electroencephalographic measurement of the response to light) in the patient were significantly prolonged at 177 msec.15 After transplantation, visual evoked responses decreased to 130 msec (normal +3 SD, <105 msec). These recorded times were p100 measurements (i.e., measurements of the time required for impulses to travel from the retina to the occipital region). Electroencephalographic wave forms in response to visual stimuli were easier to identify after transplantation, and their amplitude increased. The patient's visual acuity is now 20/40 in the right eye and 20/70 in the left.
MRI after transplantation showed a reduction in the abnormal myelin pattern (Figure 2Figure 2
Axial T2-Weighted Spin–Echo Magnetic Resonance Images in Patient 1 before and after Transplantation.). Motor-nerve conduction velocity has remained stable at 30 m per second. Epileptiform activity was noted on electroencephalographic examination before transplantation and was absent 10 months thereafter. Cerebrospinal fluid total protein levels declined gradually after transplantation (Figure 3Figure 3Cerebrospinal Fluid Total Protein Levels in Four Patients with Globoid-Cell Leukodystrophy before and after Hematopoietic Stem-Cell Transplantation.).Patient 2
The clinical course in Patient 2 began with deterioration of her vision at four years of age. One year later, a gait disturbance indicative of left-sided corticospinal dysfunction was apparent. At seven years of age, she received a marrow transplant from an HLA-identical homozygous normal sibling who had a galactocerebrosidase level of 3.9 nmol per hour per milligram of protein.
During the next seven years, the patient's gait became normal.16 Although formal neuropsychological testing has not been performed, she is now maintaining normal school performance, whereas before transplantation she was failing in school. She is independent in the activities of daily living. Areas of increased signal intensity noted in MRI scans decreased from 1992 to 1997. Defects in visual acuity have remained stable.
Patient 3
After the diagnosis of globoid-cell leukodystrophy in two siblings, Patient 3, a seven-year-old asymptomatic boy, was found to have an abnormal leukocyte galactocerebrosidase level. He received a marrow transplant at eight years of age from an HLA-identical sibling, a carrier of the disease, who had a leukocyte galactocerebrosidase level of 2.1 nmol per hour per milligram of protein.
Neuropsychological testing indicated average intelligence before transplantation. However, reading ability, visual memory, and motor abilities were below normal before transplantation and improved after engraftment (Table 2). The patient's nonverbal IQ increased remarkably beginning one year after transplantation. His adaptive skills are normal, and he is attending school. The results of the neurologic examination remain normal.
MRI revealed areas of increased signal intensity, which have decreased since engraftment (Figure 4Figure 4
Axial T2-Weighted Spin–Echo Magnetic Resonance Images Obtained 6 Months (Top) and 26 Months (Bottom) after Transplantation in Patient 3.). Figure 3 shows the levels of total protein in cerebrospinal fluid; the IgG level in cerebrospinal fluid was 11.9 mg per deciliter before transplantation and decreased to 2.6 mg per deciliter two years afterward (normal, <4.6 mg per deciliter).Patient 4
Patient 4, a two-year-old boy, was found to have galactocerebrosidase deficiency after globoid-cell leukodystrophy developed in his younger brother at four months of age and rapidly progressed to death 10 months later. Our patient underwent transplantation at the age of two years eight months with umbilical-cord blood from an unrelated donor, in which the leukocyte galactocerebrosidase level was 2.7 nmol per hour per milligram of protein.
Neuropsychological assessment before and three years after transplantation showed above-average intelligence with no abnormalities of motor, language, or perceptual function (Table 2). Although his scores relative to normal scores are lower at follow-up than at base line on the tests of nonverbal intelligence, short-term memory, and global perception, he continues to acquire skills in these areas, albeit at a slower-than-normal rate.
The neurologic examination was and continues to be normal except for Achilles-tendon contractures leading to walking on tiptoes at 10 months of age. The patient's walking and running are now approaching normal, after the injection of botulinum toxin into the gastrocnemius muscles and the use of nighttime leg splinting at five years of age. He is attending a school appropriate for his age, and his attainment of developmental milestones is normal.
The pattern of demyelination on MRI has not changed. Median nerve conduction velocity was 13 m per second before transplantation and has increased to 30 m per second three years after transplantation (Figure 5Figure 5
Median Nerve Conduction Velocity Measured before and after Hematopoietic Stem-Cell Transplantation in Patient 4.). Total protein levels in cerebrospinal fluid have decreased (Figure 3). The IgG level in cerebrospinal fluid was 8.2 mg per deciliter before hematopoietic stem-cell transplantation and 5.3 mg per deciliter two years later.Patient 5
Globoid-cell leukodystrophy was diagnosed in Patient 5 at one month of age. He was investigated because a brother had died from the disease at 13 months of age. Patient 5 underwent transplantation at two months of age with marrow from an HLA-identical twin sister who was a heterozygote with a level of enzyme activity of 1.6 nmol per hour per milligram of protein. His clinical course and condition at 16 months of age have diverged in a favorable manner from those of the older, untreated brother.
In contrast to his condition before transplantation, the patient now neither clenches his fists nor arches. There is a tendency to hyperextend his legs, and there is rigidity in all extremities. Deep-tendon reflexes are more easily elicited on the right side. No seizures have occurred. Fine-motor skills include a neat pincer grasp. He is able to reach and grab a ring without difficulty. His gross-motor skills include the ability to reach above shoulder level. He has nearly complete head control. He sits without support and assumes a crawling position. In language development, he recognizes his name, turns appropriately, and has several syllables in his age-appropriate vocabulary. Personal and social skills include playing patty-cake, waving bye-bye, and drinking from a cup.
MRI, first performed when the patient was nine months of age, showed areas of increased signal intensity in the internal capsule and frontal–parietal white matter as well as the cerebellum. Figure 3 shows the decrease in total protein in cerebrospinal fluid. The albumin index in the cerebrospinal fluid was 97.4 before transplantation and 24.2 11 months after engraftment (normal, <9). The rate of cerebrospinal fluid IgG synthesis was 106 mg per deciliter before transplantation and had decreased to 14.9 mg per deciliter by 13 months of age (normal, <8.0 mg per deciliter).
Discussion
We treated five children with globoid-cell leukodystrophy with allogeneic hematopoietic stem-cell transplantation. Two patients (Patients 1 and 2) with late-onset globoid-cell leukodystrophy had substantial neurologic disability before transplantation. Preliminary reports on both have been published elsewhere.14,16 The obvious difficulties, which included ataxia, tremors, motor incoordination (in Patient 1), and gait dysfunction (in Patient 2) resolved after transplantation. In three patients with late-onset disease who had serial evaluations (Patients 1, 3, and 4), cognition, language, and memory continue to develop normally. Patients 1, 2, 3, and 4 have demonstrated increased academic abilities in school.
MRI in two patients (Patients 1 and 3) has shown smaller areas of signal intensity since transplantation. The severity score (based on a review of the MRI scans) decreased from 10 to 9.5 in Patient 1 (from 1989 to 1997) and from 7.5 to 5.0 in Patient 3 (from 1995 to 1997).9 The severity score has remained stable in Patient 2 even though some areas of demyelination have become smaller. The MRI findings in Patient 4 have remained stable.
Cerebrospinal fluid protein levels decreased in four patients (Patients 1, 3, 4, and 5) after transplantation (Figure 3). Cerebrospinal fluid was not examined in Patient 2. Median nerve conduction velocity rose from 13 m per second to 30 per second in Patient 4 but did not change significantly in Patients 1 and 3. Such studies were not performed in Patients 2 and 5.
These signs of improvement in the central nervous system in the patients with late-onset disease are without precedent in the natural history of globoid-cell leukodystrophy.1-3,7,17,18 The normalization of enzyme activity must be considered the factor most likely to be responsible for this improvement. Another, though less likely, explanation would be that the chemotherapeutic agents used to prepare the patients for transplantation altered the rate of synthesis of toxic compounds, such as psychosine.
Heterogeneity of the disease is another explanation, because globoid-cell leukodystrophy can vary in age at onset and rate of progression among siblings, despite similar reductions in leukocyte galactocerebrosidase levels.1-3,7,19,20 In the family of Patient 1, two older sisters have leukocyte galactocerebrosidase levels that are diagnostic of globoid-cell leukodystrophy and similar to the level in the patient. These sisters are free of severe neurologic disease. The sister of Patient 3 is severely affected intellectually, and a brother has uncontrolled seizures with continued neurologic deterioration. The course of disease in Patient 4 was considerably slower than that in the brother who had the infantile form. An explanation for this heterogeneity has been sought in analysis of mutations in the galactocerebrosidase gene,21 but no differences have been found to explain the discordance. Variations in the clinical manifestations are common in milder or later-onset forms of disease in which there are slightly higher levels of residual enzyme activity.22,23
The course of the disease in Patient 5, who had the infantile form, diverges from that in his brother, but this finding should be interpreted cautiously because of the clinical variability of onset and progression of signs and symptoms.
The “twitcher” mouse, an animal model of globoid-cell leukodystrophy, has been used to study the effects of bone marrow transplantation. Despite normal enzyme activity after engraftment in this mouse model, the symptoms of hind-limb paralysis continue, although they are somewhat attenuated. Life span in this mouse is prolonged to only 100 days, despite evidence of decreased “globoid cell” neuropathology and reduced accumulation of psychosine.24-26
The differences in the results of transplantation between patients with late-onset disease and those with onset during infancy may be due to the different rates of entry of donor-derived mononuclear leukocytes, perivascular cells, and microglia into the central nervous system, which is slow and occurs over a period of months to a year after engraftment.27,28 Normal enzyme levels can be expected to be present only after such cellular changes are established.5,6,29 The balance between correction due to engraftment and ongoing destruction due to disease would be more favorable in the late-onset than in the infantile form of the disease.
The risks of hematopoietic stem-cell transplantation have decreased as a result of improved HLA tissue typing with molecular methods, depletion of T lymphocytes from the donor's marrow,30 and the use of umbilical-cord blood.31,32 Before these advances, as reports show, the results were less favorable. Teenage twins with late-onset globoid-cell leukodystrophy who were treated with allogeneic marrow transplantation died of graft-versus-host disease.20 Two patients treated in Minneapolis who had the infantile form of the disease died after transplantation, because engraftment was not sustained.14 Two other severely affected patients with infantile-onset disease, who underwent transplantation at eight and nine months of age, had progressive disease despite complete engraftment. One of these patients, from Minneapolis, has died.14 The other, treated at Duke University, has shown continued deterioration.
The infantile form of globoid-cell leukodystrophy presents a clinical dilemma, since deterioration occurs rapidly. Immediate postnatal hematopoietic stem-cell transplantation has been advocated, as has transplantation in utero.33,34
On the basis of the results in the five children described in this report, we conclude that globoid-cell leukodystrophy, especially the late-onset form, can be treated effectively with hematopoietic stem-cell transplantation.
Supported in part by grants from the National Institutes of Health (NS-29099, Study of the Value of Bone Marrow Transplant in Storage Diseases [to Dr. Krivit], and DK-38795 [to Dr. Wenger]); the Margaret Enoch Fund (to Dr. Kolodny); and Vaincre les Maladies Lysosomales (to Dr. Vanier).
NAPS See NAPS document no. 05046 for one page of supplementary material. To order, contact NAPS c/o Microfiche Publications, 248 Hempstead Tpk., West Hempstead, NY 11552.
We are indebted to Drs. Galen Breningstall, Richard P. Morse, Victor Nell, John Day, Michael Balthazor, Rita DeGasperi, and Miguel Gam Sosa and to Mr. Gil Ciocci for their clinical and laboratory expertise in caring for the patients described in this report, and to Dr. Norma K.C. Ramsay and Ms. Catherine Moen for their critical review of the manuscript.
Source Information
From the Departments of Pediatrics (W.K., C.P., J.E.W.), Neurology (E.G.S., L.A.L.), Therapeutic Radiology (K.D.), and Radiology (D.J.L.), University of Minnesota School of Medicine, Minneapolis; the Université Catholique de Louvain, Brussels, Belgium (G.C.); Duke University School of Medicine, Durham, N.C. (J.K.); Jefferson Medical College, Philadelphia (D.A.W.); New York University School of Medicine, New York (E.H.K.); and INSERM Unité 189, Lyon-Sud School of Medicine, Lyons, France (M.T.V.).
Address reprint requests to Dr. Krivit at the University of Minnesota Hospitals and Clinics, Box 477, Rm. D-548, Mayo Bldg., 420 Delaware St., S.E., Minneapolis, MN 55455.
- References
References
1
Suzuki K, Suzuki Y, Suzuki K. Galactosylceramide lipidosis: globoid-cell leukodystrophy (Krabbe disease). In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and molecular bases of inherited disease. 7th ed. Vol. 2. New York: McGraw-Hill, 1995:2671-92.
2
Kolodny EH. Globoid leukodystrophy. In: Moser HW, ed. Neurodystrophies and neurolipidoses. Vol. 66 of Handbook of clinical neurology. Amsterdam: Elsevier Science B.V., 1996:187-210.
3
Wenger DA. Krabbe disease (globoid cell leukodystrophy). In: Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, eds. The molecular and genetic basis of neurological disease. Boston: Butterworth–Heinemann, 1997:421-31.
4
Shapiro EG ,Lockman LA ,Balthazor M ,Krivit W . Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J Inherit Metab Dis 1995;18:413-429
CrossRef | Web of Science | Medline5
Krivit W ,Sung JH ,Shapiro EG ,Lockman LA . Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell Transplant 1995;4:385-392
CrossRef | Web of Science | Medline6
Krivit W, Shapiro EG, Lockman LA, et al. Bone marrow transplantation treatment for globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, and Hurler syndrome. In: Moser HW, ed. Neurodystrophies and neurolipidoses. Vol. 66 of Handbook of clinical neurology. Amsterdam: Elsevier Science B.V., 1996:87-106.
7
Phelps M ,Aicardi J ,Vanier MT . Late onset Krabbe's leukodystrophy: a report of four cases. J Neurol Neurosurg Psychiatry 1991;54:293-296
CrossRef | Web of Science | Medline8
Dhuna AC ,Toro C ,Torres F ,Kennedy WR ,Krivit W . Longitudinal neurophysiological studies in a patient with metachromatic leukodystrophy following bone marrow transplantation. Arch Neurol 1992;49:1088-1092
Web of Science | Medline9
Loes DJ ,Hite S ,Moser HW , et al. Adrenoleukodystrophy: a scoring method for brain MR observations. AJNR Am J Neuroradiol 1994;15:1761-1766
Web of Science | Medline10
Tibbling G ,Link H ,Ohman S . Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 1977;37:385-390
CrossRef | Web of Science | Medline11
Link H ,Tibbling G . Principles of albumin and IgG analyses in neurological disorders. II. Relation of the concentration of the proteins in serum and cerebrospinal fluid. Scand J Clin Lab Invest 1977;37:391-396
CrossRef | Web of Science | Medline12
Christenson RH ,Behlmer P ,Howard JF Jr ,Winfield JB ,Silverman LM . Interpretation of cerebrospinal fluid protein assays in various neurologic diseases. Clin Chem 1983;29:1028-1030
Web of Science | Medline13
Bentz JS . Laboratory investigation of multiple sclerosis. Lab Med 1995;26:393-39914
Shapiro EG, Lockman L, Kennedy W, et al. Bone marrow transplantation as treatment for globoid cell leukodystrophy. In: Desnick RJ, ed. Treatment of genetic diseases. New York: Churchill Livingstone, 1991:223-38.
15
Baker RH ,Trautmann JC ,Younge BR ,Nelson KD ,Zimmerman D . Late juvenile-onset Krabbe's disease. Ophthalmology 1990;97:1176-1180
Web of Science | Medline16
Hoogerbrugge PM ,Brouwer OF ,Bordigoni P , et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. Lancet 1995;345:1398-1402
CrossRef | Web of Science | Medline17
Kolodny EH ,Raghavan S ,Krivit W . Late-onset Krabbe disease (globoid cell leukodystrophy): clinical and biochemical features of 15 cases. Dev Neurosci 1991;13:232-239
CrossRef | Web of Science | Medline18
Hagberg B ,Kollberg H ,Sourander P ,Akesson HO . Infantile globoid cell leukodystrophy (Krabbe's disease): a clinical and genetic study of 32 Swedish cases 1953-1967. Neuropaediatrie 1969;1:74-88
CrossRef | Medline19
Verdru P ,Lammens M ,Dom R ,Van Elsen A ,Carton H . Globoid cell leukodystrophy: a family with both late infantile and adult type. Neurology 1991;41:1382-1384
Web of Science | Medline20
Choi KG ,Sung JH ,Clark HB ,Krivit W . Pathology of adult-onset globoid cell leukodystrophy (GLD). J Neuropathol Exp Neurol 1991;50:336-336 abstract.
Web of Science21
Chen YQ ,Rafi MA ,de Gala G ,Wenger DA . Cloning and expression of cDNA encoding human galactocerebrosidase, the enzyme deficient in globoid cell leukodystrophy. Hum Mol Genet 1993;2:1841-1845
CrossRef | Web of Science | Medline22
De Gasperi R ,Gama Sosa MA ,Sartorato EL , et al. Molecular heterogeneity of late-onset forms of globoid-cell leukodystrophy. Am J Hum Genet 1996;59:1233-1242
Web of Science | Medline23
Krivit W ,Lockman LA ,Watkins PA ,Hirsch J ,Shapiro EG . The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. J Inherit Metab Dis 1995;18:398-412
CrossRef | Web of Science | Medline24
Suzuki K . A genetic demyelinating disease globoid cell leukodystrophy: studies with animal models. J Neuropathol Exp Neurol 1994;53:359-363
CrossRef | Web of Science | Medline25
Suzuki K ,Taniike M . Murine model of genetic demyelinating disease: the twitcher mouse. Microsc Res Tech 1995;32:204-214
CrossRef | Web of Science | Medline26
Ohno M ,Komiyama A ,Martin PM ,Suzuki K . Proliferation of microglia/macrophages in the demyelinating CNS and PNS of twitcher mouse. Brain Res 1993;602:268-274
CrossRef | Web of Science | Medline27
Unger ER ,Sung JH ,Manivel JC ,Chenggis ML ,Blazar BR ,Krivit W . Male donor-derived cells in the brains of female sex-mismatched bone marrow transplant recipients: a Y-chromosome specific in situ hybridization study. J Neuropathol Exp Neurol 1993;52:460-470
CrossRef | Web of Science | Medline28
Peters C, Krivit W. Microglia: the effector cell of the central nervous system following bone marrow transplantation for storage diseases. In: Ringdén O, Hobbs JR, Steward CG, eds. Correction of genetic diseases by transplantation IV. London: COGENT Press, 1997:12-23.
29
Eglitis MA ,Mezey E . Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc Natl Acad Sci U S A 1997;94:4080-4085
CrossRef | Web of Science | Medline30
Wagner J ,DeFor T ,Steinbuch M , et al. Improved survival and prevention of progressive dementia in patients with selected storage diseases after unrelated donor marrow transplantation. Blood 1996;88:Suppl 1:267-267 abstract.31
Wagner JE ,Rosenthal J ,Sweetman R , et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996;88:795-802
Web of Science | Medline32
Kurtzberg J ,Laughlin M ,Graham ML , et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996;335:157-166
Full Text | Web of Science | Medline33
Peters C, Zanjani E, Krivit W. Review of considerations for hematopoietic stem cell transplantation for storage diseases both post-natal and in utero. Presented at the Second International Meeting on in Utero Stem Cell Transplantation and Gene Therapy, Nottingham, England, September 1–3, 1997. abstract.
34
Bambach BJ ,Moser HW ,Blakemore K , et al. Engraftment following in utero bone marrow transplantation for globoid cell leukodystrophy. Bone Marrow Transplant 1997;19:399-402
CrossRef | Web of Science | Medline
- Citing Articles (79)
Citing Articles
1
C N Mattar, S N Waddington, A Biswas, N Johana, X W Ng, A S Fisk, N M Fisk, L G Tan, A A Rahim, S M K Buckley, M H Tan, J Lu, M Choolani, J K Y Chan. (2012) Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems. Gene Therapy
CrossRef2
Lainie Friedman Ross. (2011) Newborn screening for lysosomal storage diseases: an ethical and policy analysis. Journal of Inherited Metabolic Disease
CrossRef3
Catarina Oliveira Miranda, Carla Andreia Teixeira, Márcia Almeida Liz, Vera Filipe Sousa, Filipa Franquinho, Giancarlo Forte, Paolo Di Nardo, Perpétua Pinto-Do-Ó, Mónica Mendes Sousa. (2011) Systemic Delivery of Bone Marrow-Derived Mesenchymal Stromal Cells Diminishes Neuropathology in a Mouse Model of Krabbe's Disease. STEM CELLS 29:11, 1738-1751
CrossRef4
Ian D. Duncan, Yoichi Kondo, Su-Chun Zhang. (2011) The Myelin Mutants as Models to Study Myelin Repair in the Leukodystrophies. Neurotherapeutics 8:4, 607-624
CrossRef5
R.L. Puckett, J.J. Orsini, G.M. Pastores, R.Y. Wang, R. Chang, C.A. Saavedra-Matiz, P.A. Torres, B. Zeng, M. Caggana, F. Lorey, J.E. Abdenur. (2011) Krabbe disease: Clinical, biochemical and molecular information on six new patients and successful retrospective diagnosis using stored newborn screening cards. Molecular Genetics and Metabolism
CrossRef6
R. L. Lieberman. (2011) Sneak peak at galactocerebrosidase, Krabbe disease's lysosomal hydrolase. Proceedings of the National Academy of Sciences 108:37, 15017-15018
CrossRef7
Ludovico Cantuti Castelvetri, Maria Irene Givogri, Hongling Zhu, Benjamin Smith, Aurora Lopez-Rosas, Xi Qiu, Richard Breemen, Ernesto Roque Bongarzone. (2011) Axonopathy is a compounding factor in the pathogenesis of Krabbe disease. Acta Neuropathologica 122:1, 35-48
CrossRef8
Raymond Y. Wang, Olaf A. Bodamer, Michael S. Watson, William R. Wilcox. (2011) Lysosomal storage diseases: Diagnostic confirmation and management of presymptomatic individuals. Genetics in Medicine 13:5, 457-484
CrossRef9
A. Biffi, P. Aubourg, N. Cartier. (2011) Gene therapy for leukodystrophies. Human Molecular Genetics 20:R1, R42-R53
CrossRef10
Hiroshi Yagasaki, Maiko Kato, Mika Ishige, Hiroyuki Shichino, Motoaki Chin, Hideo Mugishima. (2011) Successful cord blood transplantation in a 42-day-old boy with infantile Krabbe disease. International Journal of Hematology 93:4, 566-568
CrossRef11
A.B. White, F. Galbiati, M.I. Givogri, A. Lopez Rosas, X. Qiu, R. van Breemen, E.R. Bongarzone. (2011) Persistence of psychosine in brain lipid rafts is a limiting factor in the therapeutic recovery of a mouse model for Krabbe disease. Journal of Neuroscience Research 89:3, 352-364
CrossRef12
Orchard, Paul J., Wagner, John E., . (2011) Leukodystrophy and Gene Therapy with a Dimmer Switch. New England Journal of Medicine 364:6, 572-573
Full Text13
Thomas E. Lloyd, Vinay Chaudhry. 2011. Treatment and Management of Hereditary Neuropathies. , 191-213.
CrossRef14
Maurizio Scarpa, Zsuzanna Almassy, Michael Beck, Olaf Bodamer, Iain A Bruce, Linda De Meirleir, Nathalie Guffon, Encarna Guillen-Navarro, Pauline Hensman, Simon Jones, Wolfgang Kamin, Christoph Kampmann, Christina Lampe, Christine A Lavery, Elisa Leao Teles, Bianca Link, Allan M Lund, Gunilla Malm, Susanne Pitz, Michael Rothera, Catherine Stewart, Anna Tylki-Szymanska, Ans van der Ploeg, Robert Walker, Jiri Zeman, James E Wraith. (2011) Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet Journal of Rare Diseases 6:1, 72
CrossRef15
M. Aldenhoven, P.M. Hasselt, J.J. Boelens. (2010) Stamceltransplantatie voor aangeboren stofwisselingsziekten. Tijdschrift voor Kindergeneeskunde 2010:2, 88-96
CrossRef16
Lamya S. Shihabuddin, Isabelle Aubert. (2010) Stem cell transplantation for neurometabolic and neurodegenerative diseases. Neuropharmacology 58:6, 845-854
CrossRef17
Kevin Kemp, Elizabeth Mallam, Neil Scolding, Alastair Wilkins. (2010) Stem cells in genetic myelin disorders. Regenerative Medicine 5:3, 425-439
CrossRef18
Daniel Surbek, Anna Wagner, Andreina Schoeberlein. 2010. Perinatal Stem Cell Therapy. , 51-67.
CrossRef19
Vinod K. Prasad, Joanne Kurtzberg. (2010) Cord blood and bone marrow transplantation in inherited metabolic diseases: scientific basis, current status and future directions. British Journal of Haematology 148:3, 356-372
CrossRef20
Paul J. Orchard, Jakub Tolar. (2010) Transplant Outcomes in Leukodystrophies. Seminars in Hematology 47:1, 70-78
CrossRef21
Paola Luzi, Ronnie M. Abraham, Mohammad A. Rafi, Mark Curtis, D. Craig Hooper, David A. Wenger. (2009) Effects of treatments on inflammatory and apoptotic markers in the CNS of mice with globoid cell leukodystrophy. Brain Research 1300, 146-158
CrossRef22
Daniel J. Costello, April F. Eichler, Florian S. Eichler. (2009) Leukodystrophies. The Neurologist 15:6, 319-328
CrossRef23
Yassin Al-Falahi, Kristin L. Sand, Eirunn Knudsen, Bassam B. Damaj, Johannes Rolin, Azzam A. Maghazachi. (2009) Splenic natural killer cell activity in two models of experimental neurodegenerative diseases. Journal of Cellular and Molecular Medicine 13:8b, 2693-2703
CrossRef24
F. Galbiati, M.I. Givogri, L. Cantuti, A. Lopez Rosas, H. Cao, R. van Breemen, E.R. Bongarzone. (2009) Combined hematopoietic and lentiviral gene-transfer therapies in newborn Twitcher mice reveal contemporaneous neurodegeneration and demyelination in Krabbe disease. Journal of Neuroscience Research 87:8, 1748-1759
CrossRef25
Michelina Strazza, Alice Luddi, Marica Carbone, Mohammad A. Rafi, Elvira Costantino-Ceccarini, David A. Wenger. (2009) Significant correction of pathology in brains of twitcher mice following injection of genetically modified mouse neural progenitor cells. Molecular Genetics and Metabolism 97:1, 27-34
CrossRef26
Patricia K. Duffner, Kabir Jalal, Randolf L. Carter. (2009) The Hunter's Hope Krabbe Family Database. Pediatric Neurology 40:1, 13-18
CrossRef27
V. K. Prasad, A. Mendizabal, S. H. Parikh, P. Szabolcs, T. A. Driscoll, K. Page, S. Lakshminarayanan, J. Allison, S. Wood, D. Semmel, M. L. Escolar, P. L. Martin, S. Carter, J. Kurtzberg. (2008) Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes. Blood 112:7, 2979-2989
CrossRef28
F. Sedel, A. Tourbah, B. Fontaine, C. Lubetzki, N. Baumann, J.-M. Saudubray, O. Lyon-Caen. (2008) Leukoencephalopathies associated with inborn errors of metabolism in adults. Journal of Inherited Metabolic Disease 31:3, 295-307
CrossRef29
Z Y Lim, A Y L Ho, S Abrahams, A Fensom, M Aldouri, A Pagliuca, C Shaw, G J Mufti. (2008) Sustained neurological improvement following reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation for late-onset Krabbe disease. Bone Marrow Transplantation 41:9, 831-832
CrossRef30
Gregory M. Enns, Stephen L. Huhn. (2008) Central nervous system therapy for lysosomal storage disorders. Neurosurgical FOCUS 24:3-4, E12
CrossRef31
D. C. Hess, C. V. Borlongan. (2008) Stem cells and neurological diseases. Cell Proliferation 41, 94-114
CrossRef32
B. K Ormerod, T. D Palmer, M. A Caldwell. (2008) Neurodegeneration and cell replacement. Philosophical Transactions of the Royal Society B: Biological Sciences 363:1489, 153-170
CrossRef33
Carmella van de Ven, Daniel Collins, M. Brigid Bradley, Erin Morris, Mitchell S. Cairo. (2007) The potential of umbilical cord blood multipotent stem cells for nonhematopoietic tissue and cell regeneration. Experimental Hematology 35:12, 1753-1765
CrossRef34
Paul J. Orchard, Bruce R. Blazar, John Wagner, Lawrence Charnas, William Krivit, Jakub Tolar. (2007) Hematopoietic Cell Therapy for Metabolic Disease. The Journal of Pediatrics 151:4, 340-346
CrossRef35
Darshong Lin, Anthony Donsante, Shannon Macauley, Beth Levy, Carole Vogler, Mark S Sands. (2007) Central Nervous System-directed AAV2/5-Mediated Gene Therapy Synergizes with Bone Marrow Transplantation in the Murine Model of Globoid-cell Leukodystrophy. Molecular Therapy 15:1, 44-52
CrossRef36
F. Sedel. (2007) Leucodistrofie dell???adulto. EMC - Neurologia 7:2, 1-12
CrossRef37
Michael J. J. Kim, James M. Provenzale, Meng Law. (2006) Magnetic Resonance and Diffusion Tensor Imaging in Pediatric White Matter Diseases. Topics in Magnetic Resonance Imaging 17:4, 265-274
CrossRef38
D. Dolcetta, L. Perani, M. I. Givogri, F. Galbiati, S. Amadio, U. Del Carro, G. Finocchiaro, A. Fanzani, S. Marchesini, L. Naldini, M. G. Roncarolo, E. Bongarzone. (2006) Design and optimization of lentiviral vectors for transfer of GALC expression in Twitcher brain. The Journal of Gene Medicine 8:8, 962-971
CrossRef39
Jaap Jan Boelens. (2006) Trends in haematopoietic cell transplantation for inborn errors of metabolism. Journal of Inherited Metabolic Disease 29:2-3, 413-420
CrossRef40
Sandhya Kharbanda, Angela Panoskaltsis-Mortari, Imad Y. Haddad, Bruce R. Blazar, Paul J. Orchard, David N. Cornfield, Satkiran S. Grewal, Charles Peters, Warren E. Regelmann, Carlos E. Milla, K. Scott Baker. (2006) Inflammatory Cytokines and the Development of Pulmonary Complications after Allogeneic Hematopoietic Cell Transplantation in Patients with Inherited Metabolic Storage Disorders. Biology of Blood and Marrow Transplantation 12:4, 430-437
CrossRef41
Serena Pellegatta, Patrizia Tunici, Pietro Luigi Poliani, Diego Dolcetta, Laura Cajola, Cristina Colombelli, Emilio Ciusani, Stefano Di Donato, Gaetano Finocchiaro. (2006) The therapeutic potential of neural stem/progenitor cells in murine globoid cell leukodystrophy is conditioned by macrophage/microglia activation. Neurobiology of Disease 21:2, 314-323
CrossRef42
Paul L. Martin, Shelly L. Carter, Nancy A. Kernan, Indira Sahdev, Donna Wall, Daniel Pietryga, John E. Wagner, Joanne Kurtzberg. (2006) Results of the Cord Blood Transplantation Study (COBLT): Outcomes of Unrelated Donor Umbilical Cord Blood Transplantation in Pediatric Patients with Lysosomal and Peroxisomal Storage Diseases. Biology of Blood and Marrow Transplantation 12:2, 184-194
CrossRef43
S. Raghavan, B. Zeng, P. A. Torres, G. M. Pastores, E. H. Kolodny, J. Kurtzberg, W. Krivit. (2005) Globoid cell leukodystrophy (Krabbe disease): Normal umbilical cord blood galactocerebrosidase activity and polymorphic mutations. Journal of Inherited Metabolic Disease 28:6, 1005-1009
CrossRef44
Gregory M Pastores, Natalie L Barnett. (2005) Current and emerging therapies for the lysosomal storage disorders. Expert Opinion on Emerging Drugs 10:4, 891-902
CrossRef45
Maria B. Weimer, Amparo Gutierrez, Gary B. Baskin, Juan T. Borda, Ronald S. Veazey, Leann Myers, Kathrine M. Phillippi-Falkenstein, Bruce A. Bunnell, Marion S. Ratterree, John D. England. (2005) Serial electrophysiologic studies in rhesus monkeys with Krabbe disease. Muscle & Nerve 32:2, 185-190
CrossRef46
Jeffrey L. Ecker, Michael F. Greene. (2005) The Case Against Private Umbilical Cord Blood Banking. Obstetrics & Gynecology 105:6, 1282-1284
CrossRef47
Escolar, Maria L., Poe, Michele D., Provenzale, James M., Richards, Karen C., Allison, June, Wood, Susan, Wenger, David A., Pietryga, Daniel, Wall, Donna, Champagne, Martin, Morse, Richard, Krivit, William, Kurtzberg, Joanne, . (2005) Transplantation of Umbilical-Cord Blood in Babies with Infantile Krabbe's Disease. New England Journal of Medicine 352:20, 2069-2081
Full Text48
Weinberg, Kenneth I., . (2005) Early Use of Drastic Therapy. New England Journal of Medicine 352:20, 2124-2126
Full Text49
Jin-Song Shen, Xing-Li Meng, Takashi Yokoo, Ken Sakurai, Kazuhiko Watabe, Toya Ohashi, Yoshikatsu Eto. (2005) Widespread and highly persistent gene transfer to the CNS by retrovirus vectorin utero: implication for gene therapy to Krabbe disease. The Journal of Gene Medicine 7:5, 540-551
CrossRef50
Xing-Li Meng, Jin-Song Shen, Kazuhiko Watabe, Toya Ohashi, Yoshikatsu Eto. (2005) GALC transduction leads to morphological improvement of the twitcher oligodendrocytes in vivo. Molecular Genetics and Metabolism 84:4, 332-343
CrossRef51
Hatice Asuman Özkara. (2004) Recent advances in the biochemistry and genetics of sphingolipidoses. Brain and Development 26:8, 497-505
CrossRef52
Richard L. Proia, Yun-Ping Wu. (2004) Blood to brain to the rescue. Journal of Clinical Investigation 113:8, 1108-1110
CrossRef53
Edward A. Neuwelt. (2004) Mechanisms of Disease: The Blood-Brain Barrier. Neurosurgery 54:1, 131-142
CrossRef54
T. M. Burns, M. M. Ryan, B. Darras, H. R. Jones. (2003) Current Therapeutic Strategies for Patients With Polyneuropathies Secondary to Inherited Metabolic Disorders. Mayo Clinic Proceedings 78:7, 858-868
CrossRef55
Patricia A. Galvin-Parton. (2003) Screening for GALC to make neonatal diagnosis and initial neonatal stem cell treatment with umbilical cord blood. Pediatric Transplantation 7:2, 83-85
CrossRef56
Maurizio Caniglia, Ippolita Rana, Rita Maria Pinto, Giuseppe Fariello, Roberta Caruso, Adriano Angioni, Carlo Dionisi Vici, Gaetano Sabetta, Giulio De Rossi. (2002) Allogeneic bone marrow transplantation for infantile globoid-cell leukodystrophy (Krabbe's disease). Pediatric Transplantation 6:5, 427-431
CrossRef57
Raphael Schiffmann, Roscoe O. Brady. (2002) New Prospects for the Treatment of Lysosomal Storage Diseases. Drugs 62:5, 733-742
CrossRef58
SANGITA BISWAS AND, STEVEN M. LE VINE. (2002) Substrate-Reduction Therapy Enhances the Benefits of Bone Marrow Transplantation in Young Mice with Globoid Cell Leukodystrophy. Pediatric Research 51:1, 40-47
CrossRef59
C.G. Janson, T.M. Ramesh, M.J. During, P. Leone, J. Heywood. (2001) Human Intrathecal Transplantation of Peripheral Blood Stem Cells in Amyotrophic Lateral Sclerosis. Journal of Hematotherapy <html_ent glyph="@amp;" ascii="&"/> Stem Cell Research 10:6, 913-915
CrossRef60
Sangita Biswas, David M. Pinson, Illya G. Bronshteyn, Steven M. LeVine. (2001) IL-6 deficiency allows for enhanced therapeutic value after bone marrow transplantation across a minor histocompatibility barrier in the twitcher (globoid cell leukodystrophy) mouse. Journal of Neuroscience Research 65:4, 298-307
CrossRef61
A. Luddi, M. Volterrani, M. Strazza, A. Smorlesi, M.A. Rafi, J. Datto, D.A. Wenger, E. Costantino-Ceccarini. (2001) Retrovirus-Mediated Gene Transfer and Galactocerebrosidase Uptake into Twitcher Glial Cells Results in Appropriate Localization and Phenotype Correction. Neurobiology of Disease 8:4, 600-610
CrossRef62
Johannes Berger, Hugo W. Moser, Sonja Forss-Petter. (2001) Leukodystrophies: recent developments in genetics, molecular biology, pathogenesis and treatment*. Current Opinion in Neurology 14:3, 305-312
CrossRef63
Kikue Nakano, Makoto Migita, Hideki Mochizuki, Takashi Shimada. (2001) DIFFERENTIATION OF TRANSPLANTED BONE MARROW CELLS IN THE ADULT MOUSE BRAIN1. Transplantation 71:12, 1735-1740
CrossRef64
Edward M. Kaye. (2001) Lysosomal storage diseases. Current Treatment Options in Neurology 3:3, 249-256
CrossRef65
Jody Donahue, Elisabeth Gilpin, Tzong-Hae Lee, Michael P. Busch, Michael Croft, Ewa Carrier. (2001) MICROCHIMERISM DOES NOT INDUCE TOLERANCE AND SUSTAINS IMMUNITY AFTER IN UTERO TRANSPLANTATION1. Transplantation 71:3, 359-368
CrossRef66
Livia Poenaru. (2001) From gene transfer to gene therapy in lysosomal storage diseases affecting the central nervous system. Annals of Medicine 33:1, 28-36
CrossRef67
C Caillaud, L Poenaru. (2000) Gene therapy in lysosomal diseases. Biomedicine & Pharmacotherapy 54:10, 505-512
CrossRef68
Colin G Steward. (2000) Stem cell transplantation for non-malignant disorders. Best Practice & Research Clinical Haematology 13:3, 343-363
CrossRef69
Yun-Ping Wu, Eileen McMahon, Meredith R. Kraine, Roland Tisch, Anthony Meyers, Jeffrey Frelinger, Glenn K. Matsushima, Kinuko Suzuki. (2000) Distribution and Characterization of GFP+ Donor Hematogenous Cells in Twitcher Mice after Bone Marrow Transplantation. The American Journal of Pathology 156:6, 1849-1854
CrossRef70
David A. Wenger, Mohammad A. Rafi, Paola Luzi, Jeffrey Datto, Elvira Costantino-Ceccarini. (2000) Krabbe Disease: Genetic Aspects and Progress toward Therapy. Molecular Genetics and Metabolism 70:1, 1-9
CrossRef71
Steven M. LeVine, Tetyana V. Pedchenko, Illya G. Bronshteyn, David M. Pinson. (2000) L-cycloserine slows the clinical and pathological course in mice with globoid cell leukodystrophy (twitcher mice). Journal of Neuroscience Research 60:2, 231-236
CrossRef72
Omer N. Koç, Charles Peters, Patrick Aubourg, Shrini Raghavan, Stephanie Dyhouse, Rita DeGasperi, Edwin H. Kolodny, Yoav BenYoseph, Stanton L. Gerson, Hillard M. Lazarus, Arnold I. Caplan, Paul A. Watkins, William Krivit. (1999) Bone marrow–derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. Experimental Hematology 27:11, 1675-1681
CrossRef73
William Krivit, Patrick Aubourg, Elsa Shapiro, Charles Peters. (1999) Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndrome. Current Opinion in Hematology 6:6, 377
CrossRef74
Payam Rezaie, David Male. (1999) Colonisation of the developing human brain and spinal cord by microglia: a review. Microscopy Research and Technique 45:6, 359-382
CrossRef75
P Rezaie. (1999) Microglia in the human fetal spinal cord—patterns of distribution, morphology and phenotype. Developmental Brain Research 115:1, 71-81
CrossRef76
William Krivit, Charles Peters, Elsa G. Shapiro. (1999) Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Current Opinion in Neurology 12:2, 167-176
CrossRef77
Yujing Liu, Ryuichi Wada, Hiromichi Kawai, Kazunori Sango, Chuxia Deng, Tadashi Tai, Michael P. McDonald, Kristlyn Araujo, Jacqueline N. Crawley, Uwe Bierfreund, Konrad Sandhoff, Kinuko Suzuki, Richard L. Proia. (1999) A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder. Journal of Clinical Investigation 103:4, 497-505
CrossRef78
Thomas M Daly, Mark S Sands. (1998) Gene therapy for lysosomal storage diseases. Expert Opinion on Investigational Drugs 7:10, 1673-1682
CrossRef79
Lori L. Billinghurst, Rosanne M. Taylor, Evan Y. Snyder. (1998) Remyelination: Cellular and gene therapy. Seminars in Pediatric Neurology 5:3, 211-228
CrossRef
